Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden.
Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
| Brand name(s) | Ingredients (INN) | Food and Drug Administration (FDA) approval date | European Medicines Agency (EMA) approval date | Health Canada approval date | Company | Single-tablet regimen? | ||||
| NRTIs / NtRTIs | NNRTI | INSTI | PI | PK enhancer | ||||||
| Combivir | lamivudine zidovudine |
September 26, 1997 | ViiV Healthcare | No | ||||||
| Kaletra (developed countries) Aluvia (developing countries) |
lopinavir | ritonavir | September 15, 2000 | Abbott Laboratories | No | |||||
| Trizivir | abacavir lamivudine zidovudine |
November 15, 2000 | ViiV Healthcare | Yes | ||||||
| Epzicom (US) Kivexa (EU, RU) |
abacavir lamivudine |
August 2, 2004 | ViiV Healthcare | No | ||||||
| Generics, e.g., Triomune | lamivudine stavudine |
nevirapine | (not approved) | (many companies) | Yes | |||||
| Generics, e.g., Duovir-N | lamivudine zidovudine |
nevirapine | (not approved) | (many companies) | Yes | |||||
| Truvada | emtricitabine tenofovir disoproxil |
August 2, 2004 | Gilead Sciences | No | ||||||
| Atripla | emtricitabine tenofovir disoproxil |
efavirenz | July 12, 2006 | Gilead Sciences Bristol-Myers Squibb |
Yes | |||||
| Complera (US) Eviplera (EU, RU) |
emtricitabine tenofovir disoproxil |
rilpivirine | August 10, 2011 | Gilead Sciences Janssen Pharmaceutica |
Yes | |||||
| Stribild | emtricitabine tenofovir disoproxil |
elvitegravir | cobicistat | August 27, 2012 | Gilead Sciences | Yes | ||||
| Triumeq | abacavir lamivudine |
dolutegravir | August 22, 2014 | ViiV Healthcare | Yes | |||||
| Evotaz | atazanavir | cobicistat | January 29, 2015 | Bristol-Myers Squibb | No | |||||
| Prezcobix (US) Rezolsta (EU) |
darunavir | cobicistat | January 29, 2015 | Janssen Pharmaceutica | No | |||||
| Dutrebis | lamivudine | raltegravir | February 6, 2015 | Merck & Co. | No | |||||
| Genvoya | emtricitabine tenofovir alafenamide |
elvitegravir | cobicistat | November 5, 2015 | Gilead Sciences | Yes | ||||
| Odefsey | emtricitabine tenofovir alafenamide |
rilpivirine | March 1, 2016 | Gilead Sciences | Yes | |||||
| Descovy | emtricitabine tenofovir alafenamide |
April 4, 2016 | Gilead Sciences | No | ||||||
| Juluca | rilpivirine | dolutegravir | November 21, 2017 | ViiV Healthcare | Yes | |||||
| Symfi, Symfi Lo | lamivudine tenofovir disoproxil |
efavirenz | February 5, 2018 (Symfi Lo) March 22, 2018 (Symfi) |
Mylan | Yes | |||||
| Biktarvy | emtricitabine tenofovir alafenamide |
bictegravir | February 7, 2018 | Gilead Sciences | Yes | |||||
| Cimduo, Temixys | lamivudine tenofovir disoproxil |
February 28, 2018 | Mylan | No | ||||||
| Symtuza | emtricitabine tenofovir alafenamide |
darunavir | cobicistat | July 17, 2018 | Janssen Pharmaceutica | Yes | ||||
| Delstrigo | lamivudine tenofovir disoproxil |
doravirine | August 30, 2018 | Merck & Co. | Yes | |||||
| Dovato | lamivudine | dolutegravir | April 8, 2019 | ViiV Healthcare | Yes | |||||
| Cabenuva | rilpivirine | cabotegravir | January 21, 2021 | March 18, 2020[1][2] | ViiV Healthcare | No | ||||
References
- ↑ "Cabenuva Product information". Health Canada. 25 April 2012. Retrieved 22 January 2021.
- ↑ "ViiV Healthcare announces first global regulatory approval of Cabenuva; the first complete, long-acting, regimen for the treatment of HIV". GSK. Retrieved 23 January 2021.
External links
- "Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets". ClinicalInfo.
This article incorporates text from this source, which is in the public domain.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.